Avid Bioservices Inc (CDMO)

[jazzbeerman]

James Robinson (at Tulane) has been the CHAVI hybridoma go-to-guy from day 1. Any interesting abs found in patients from CHAVI 005 or 006 protocols go to Robinson to make mabs for further study. So far all I've seen mentioned in Haynes' patent applications (and presentations) has been: bavituximab, tarvacin, 3G4, 2AG4, IS1, IS2, IS6. If Haynes is submitting patent applications that say:

IS1 can be safely used as a therapeutic Mab for treatment of HIV infected
subjects.

and can "broadly neutralize HIV in an unprecedented manner"


I'm very confident that we'll see a paper discussing WHY he said that in his patent application.

Also, obviously, you'd expect the work to 'continue'....


- funded by whom?....
Well, who's been funding it so far?....


j